Table 1.

The effect of combined treatment with anti-IL-9 and anti-IL-5 or their isotype control on cell profiles in differenttissue compartments

	IsC of anti-IL9 + IsC of anti-IL-5	Anti-IL-9 + Anti-IL-5	Anti-IL-5 + IsC of anti-IL-9	Anti-IL-9 + IsC of anti-IL-5
Bone marrow eosinophils(%):	19.3 ± 2.5	3.6 ± 0.6**	3.6 ± 0.7**	18.4 ± 2.2
Immature eos. (%)	13.4 ± 2.1	2.3 ± 0.4**	2.3 ± 0.4**	14.8 ± 2.1
Mature eos. (%)	5.9 ± 0.6	1.2 ± 0.3**	1.4 ± 0.5**	3.7 ± 0.4*
Blood cells (total no., ×106/ml):	1.9 ± 0.2	1.5 ± 0.6	1.3 ± 0.3	1.7 ± 0.2
Neutrophils (×106/ml)	0.7 ± 0.1	0.8 ± 0.3	0.56 ± 0.1	0.7 ± 0.1
Eosinophils (×106/ml)	0.3 ± 0.1	0.1 ± 0.03*	0.1 ± 0.02*	0.3 ± 0.04
Monocytes (×106/ml)	0.3 ± 0.04	0.2 ± 0.04	0.2 ± 0.1	0.2 ± 0.03
Lymphocytes (×106/ml)	0.5 ± 0.1	0.4 ± 0.2	0.5 ± 0.1	0.5 ± 0.1
BAL cells (total no., ×104/ml):	109.3 ± 1.9	44.5 ± 7.6	45.9 ± 3.3	92.4 ± 8.8
Macrophages (×104/ml)	18.9 ± 1.9	11.8 ± 1.0	11.7 ± 0.3	16.9 ± 3.4
Neutrophils (×104/ml)	5.4 ± 1.7	3.8 ± 0.7	4.6 ± 1.0	4.9 ± 1.2
Eosinophils (×104/ml)	67.9 ± 15.1	20.0 ± 6.3*	18.8 ± 2.1*	54.8 ± 6.0
Lymphocytes (×104/ml)	16.8 ± 3.2	8.5 ± 1.8	10.7 ± 1.2	15.5 ± 4.5

Balb/c mice sensitized to OVA were subjected to repeated allergen exposure (OVA; 100 μg i.n. on five consecutive days).

Neutralizing anti-IL-9 (100 μg/animal i.p.) and anti-IL-5 (50 μg/animal i.p.) treatment or their isotype controls treatment, or single antibody in a combination with respective isotype control, were given before the allergen exposure. BAL was performed 24 hours after the last allergen exposure. Data represent mean ± SEM (n = 5 per point). * p < 0.05 and ** p < 0.01 compared with the isotype control antibodies treated group. IsC – isotype control.